OTCMKTS:SZLSF Stagezero Life Sciences (SZLSF) Stock Price, News & Analysis $0.0010 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About Stagezero Life Sciences Stock (OTCMKTS:SZLSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SZLSF alerts:Sign Up Key Stats Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.0010▼$0.0010VolumeN/AAverage VolumeN/AMarket Capitalization$123.55 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview StageZero Life Sciences Ltd. is a Canadian life sciences company focused on developing molecular diagnostic technologies and delivering laboratory-based healthcare services. The company’s activities center on blood-based testing intended to support the detection and management of cancer and other health conditions. StageZero’s principal diagnostic platform, Aristotle, is designed to analyze gene-expression patterns in a blood sample and identify molecular signals associated with multiple cancers. The company has also pursued telehealth and laboratory services intended to facilitate remote access to testing and clinical care, including sample collection and diagnostic assessment. StageZero serves patients and healthcare providers through its Canadian operations and has sought to expand access to its testing services in North America. The availability and regulatory status of individual tests and services may vary by jurisdiction.AI Generated. May Contain Errors. Read More Receive SZLSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stagezero Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SZLSF Stock News HeadlinesStageZero Life Sciences Ltd. (SZLSF)July 27, 2024 | finance.yahoo.comStageZero Life Sciences Ltd: StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational UpdateMay 17, 2024 | finanznachrichten.deA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 28 at 1:00 AM | TradeSmith (Ad)StageZero Life Sciences Ltd: StageZero Life Sciences Provides an Update on Application for Management Cease Trade OrderApril 5, 2024 | finanznachrichten.deStagezero Life Sciences GAAP EPS of -$0.01, revenue of $0.75MNovember 15, 2023 | seekingalpha.comStageZero Life Sciences, Ltd Announces Results of Resolutions at Annual and Special MeetingJune 7, 2023 | finance.yahoo.comDually-Listed Healthcare Stock Rallies On Q1 ResultsMay 17, 2023 | theglobeandmail.comStageZero to Issue Q1 2023 Financial Results After Market Closes May 15, 2023May 15, 2023 | finance.yahoo.comSee More Headlines SZLSF Stock Analysis - Frequently Asked Questions How have SZLSF shares performed this year? Stagezero Life Sciences' stock was trading at $0.0005 on January 1st, 2026. Since then, SZLSF stock has increased by 100.0% and is now trading at $0.0010. How do I buy shares of Stagezero Life Sciences? Shares of SZLSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryN/A Current SymbolOTCMKTS:SZLSF CIK1454263 Webwww.stagezerolifesciences.com Phone(855) 420-7140Fax905-209-2031Employees40Year Founded1998Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares123,550,000Free Float120,415,000Market Cap$123.55 thousand OptionableNot Optionable Beta-3.98 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:SZLSF) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersThe Department of War is on a gold mine's filingsOn May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...Behind the Markets | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stagezero Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stagezero Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
